The Japan AI in Oncology Market was valued at $171.5 Million in 2024 and projected to reach to $858.7 Million by 2029, representing a compound annual growth rate of 30.8%. Japan's AI in Oncology market is poised for exceptional growth over the next five years, driven by the convergence of an aging population, advanced healthcare infrastructure, and substantial government backing for digital health transformation.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Japan's AI in Oncology market is projected to grow from $171.5 million in 2024 to $858.7 million by 2029, representing a robust 30.8% CAGR, outpacing the global average of 29.4%.
Japan's rapidly aging demographic, with one of the world's highest life expectancies, is increasing cancer incidence rates and creating substantial demand for advanced AI-powered diagnostic and treatment solutions.
Japan's world-class healthcare system, coupled with significant government investment in digital health and precision medicine initiatives, provides an ideal environment for AI oncology adoption and innovation.
Japan is positioning itself as a global leader in precision oncology, with strong institutional support for AI-driven early cancer detection, personalized treatment planning, and genomic analysis technologies.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | DEEP LEARNING (Type) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 29.4% from 2024 to 2029 |
| Largest Segment | SOLID TUMORS (Cancer Type) |
| Market Size Base Year (Billions) | ~USD 2.45 (2024) |
| Revenue Forecast (Billions) | ~USD 8.9 (2029) |
| Segments Covered | Technology, Type, Application, Cancer Type, End User, Player Type, Deployment Model |
7 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTIONS | 10.4 | 13.9 | 17.9 | 23.2 | 30.2 | 39.3 | 51.3 | 67.2 | 88.3 | 30.4 |
| GOVERNMENT & REGULATORY AGENCIES | 4.1 | 5.4 | 6.9 | 8.8 | 11.3 | 14.5 | 18.7 | 24.1 | 31.2 | 28.6 |
| HEALTHCARE PAYERS | 2.5 | 3.4 | 4.3 | 5.6 | 7.2 | 9.4 | 12.2 | 15.9 | 20.8 | 29.9 |
| HEALTHCARE PROVIDERS | 46.9 | 63.3 | 82.3 | 107.3 | 140.5 | 184.4 | 242.7 | 320.6 | 424.6 | 31.5 |
| MEDICAL DEVICE/EQUIPMENT COMPANIES | 9 | 11.9 | 15.2 | 19.5 | 25.1 | 32.3 | 41.8 | 54.2 | 70.5 | 29.1 |
| OTHER END USERS | 2 | 2.6 | 3.4 | 4.3 | 5.5 | 7.1 | 9 | 11.6 | 14.8 | 27.9 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 23.7 | 31.9 | 41.4 | 53.7 | 70 | 91.6 | 120.1 | 158 | 208.4 | 30.9 |
| TOTAL | 98.6 | 132.5 | 171.5 | 222.6 | 289.8 | 378.5 | 495.8 | 651.7 | 858.7 | 30.8 |
Japan's AI in Oncology market was valued at $171.5 million in 2024 and is projected to reach $858.7 million by 2029.
Japan's AI in Oncology market is growing at a compound annual growth rate (CAGR) of 30.8% from 2024 to 2029.
Key drivers include Japan's aging population, advanced healthcare infrastructure, high healthcare spending, government precision medicine initiatives, and strong collaboration between medical institutions and technology companies.
Japan's oncology sector is increasingly adopting AI diagnostic tools, treatment planning systems, predictive analytics, and personalized medicine platforms for cancer care.
Japan leads Asia Pacific in AI oncology adoption due to its advanced healthcare system, regulatory maturity, high investment capacity, and strong institutional support for precision medicine.
The study involved significant activities to estimate the current size of the AI in oncology. Exhaustive secondary research was done to collect information on the AI in oncology market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the AI in oncology market.
This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in oncology solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.
Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in oncology vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.
In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts, such as Chief Executive Officers (CEOs), Vice Presidents (VPs), marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the AI in oncology market.
After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also undertaken to identify the segmentation types, industry trends, competitive landscape of AI in oncology solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.
In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.
Breakdown of Primary Participants:
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Tiers of companies are defined based on their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in oncology. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

After arriving at the overall market size using the market size estimation processes explained above, the market was split into several segments and subsegments. The data triangulation and market breakup procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment. The data was triangulated by studying various factors and trends from both the demand and supply sides.
AI I in oncology is the utilization of AI tools such as machine learning, natural language processing, and computer vision, among others to analyze genomic data and large gene mutations that are unique to an individual’s cancer profile. These AI tools are adopted by various end-users including labs, research centers, hospitals, and biotechnology & pharmaceuticals, among others to address the global cancer burden and the need for precision medicine in oncology.
Further, AI boosts the speed and accuracy of cancer diagnosis and screening. The major developments include:
Full forecast, segment splits, and company analysis for all AI in Oncology Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report